UNSPSC 51271704: Eugenol

This classification denotes an anesthetic agent with the molecular formula C10H12O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 3T8H1794QW, chemically known as 1,3,4-eugenol but generally known as eugenol, which bears US NIH Compound Identifier 3314. European Medicines Agency schedules Eugenol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB13776MIG. As of Q4 2014, EUGENOL remains the US FDA Preferred Term for this commodity.

Eugenol bears US NLM identifiers UMLS ID C0015153 and NCI Concept Code C75095. SMILES: COC1=C(C=CC(=C1)CC=C)O.

UNSPSC 51271704 Eugenol is a Commodity code for pharmaceutical and chemical supply products purchased through state and local cooperative purchasing arrangements. State and local governments acquire eugenol and similar pharmaceutical intermediates as components of broader multi-source generic pharmaceutical and over-the-counter product procurement programs administered through multistate cooperative purchasing alliances. The issuing bodies soliciting under this code include state departments of administration and health, participating state and local government facilities, and county and municipal agencies that leverage cooperative purchasing vehicles to consolidate pharmaceutical procurement across member jurisdictions.

The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued a Request for Proposal on January 20, 2026 (S1070000015802) to establish multiple contracts for generic multi-source pharmaceuticals and OTC products for distribution across participating state and local government facilities in Minnesota, Oregon, and other member states. The RFP, due March 26, 2026, requires manufacturers to supply comprehensive product lines with specific National Drug Codes, SKUs, and UPCs, with all products available by May 15, 2026 and contract effectiveness set for July 1, 2026. Vendors must maintain relationships with authorized wholesalers (AmerisourceBergen/Cencora, Cardinal Health, and Morris & Dickson), certify compliance with current Good Manufacturing Practices and the Drug Supply Chain Security Act, carry insurance including $5 million commercial general liability coverage, and accept a 3 percent administrative fee on contract purchases. Evaluation emphasizes price competitiveness (75 percent) and submission through the ePro procurement system with pricing submitted in CSV format by the February 18, 2026 question cutoff. The contract term spans two years for new vendors with optional extensions, or amendments through June 30, 2028 for incumbents.